Open AccessSafety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections
Author(s) -
John S. Bradley,
Tinatin Antadze,
Borislav Ninov,
Mohammed S Tayob,
Natasha Broyde,
Joan R. Butterton,
Margaret Z Chou,
Carisa S De Anda,
Jason Y. Kim,
P.S. Sears
Publication year - 2020
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003010
Subject(s) - medicine , clinical endpoint , adverse effect , clinical trial , randomized controlled trial , clinical efficacy , phases of clinical research
Tedizolid phosphate is an oxazolidinone prodrug approved in 2014 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs); however, efficacy has not previously been evaluated in children. This study compared the safety and efficacy of tedizolid (administered as tedizolid phosphate) with active antibacterial comparators for the treatment of ABSSSIs in adolescents.